Long-Term Study of MP-214 in Patients With Schizophrenia
Long-Term Extension Study of MP-214 in Patients With Schizophrenia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan
-
-
-
-
-
Seoul, South Korea
-
-
-
-
-
Taipei, Taiwan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent obtained from the patient before the completion of Study A002-A4
- Patients who have completed the A002-A4 study
Exclusion Criteria:
- Patients who are experiencing ongoing, uncontrolled, clinically significant adverse events (AEs), as judged by the investigator (or subinvestigator)
The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: MP-214 3mg
|
In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214).
In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214.
After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
|
|
Experimental: MP-214 6mg
|
In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214).
In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214.
After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
|
|
Experimental: MP-214 9mg
|
In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214).
In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214.
After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
|
|
Active Comparator: Risperidone 4mg
|
In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4.
In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214.
After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time Frame: Up to 60 weeks (Treatment Period (48 weeks) and Follow-up Period (12 weeks))
|
The Numbers show Subjects with at least one Adverse Event
|
Up to 60 weeks (Treatment Period (48 weeks) and Follow-up Period (12 weeks))
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A002-A5
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.